Short answer
Eledon Pharmaceuticals, Inc. (ELDN) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$4M
- +77.5% YoY · +87.6% QoQ
- EPS (diluted)
- −$0.04
- +81.0% YoY · +84.6% QoQ
Source: XBRL data from the Eledon Pharmaceuticals, Inc. (ELDN) Q3 2026 10-Q on SEC EDGAR. USD.
Eledon Pharmaceuticals, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no approved products or product sales
- Operating margin not meaningful, operating loss $21.7M vs $19.1M YoY
- R&D expenses $17.8M, up $2.8M YoY, driven by $5.1M higher manufacturing costs
- Cash, equivalents and short-term investments $69.7M, operating cash use $64.3M for nine months
- Phase 3 LEGACY planned for late 2026, additional financing required, substantial doubt about going concern
Risk Factors
- Newly disclosed going-concern risk: $69.7 million liquidity does not fund operations for at least twelve months
- Clinical-development risk: Phase 3 kidney-transplant trial and islet-cell program require substantial additional financing
- Regulatory risk: 2025 Trump executive orders may alter FDA rules and delay approvals
- Manufacturing risk: no redundant supply arrangements for custom drug-production materials
- Competitive risk: Vertex and other larger companies developing immune-evasive islet-cell therapies
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Eledon Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.